Will the trend of combining API and drug-product development and manufacturing services into a “one-stop shop” business model for CDMOs continue? DCAT Value Chain Insights examines recent deals and investments. Tracking activity…
A recent analysis by researchers at the Olin Business School at Washington University in St. Louis, Missouri, examines the US manufacturing base for active pharmaceutical ingredients (APIs) for essential medicines…
Which modality, small molecules or biologics, leads among the top-selling products? A look at the top-selling products industry-wide and blockbusters from select leading bio/pharma companies provides the answer. Modality of…
Drug Pricing Reform: The Impact on Drug Development
The Congressional Budget Office (CBO) released a simulation model for analyzing the impact of US legislative drug pricing proposals on new drug development. The CBO projects that certain proposals, if…
Global API Sourcing: Will Policy Impact Current Practice?
The US and the EU are continuing to advance their assessment of their supply chains for regulatory starting materials, intermediates, and APIs for essential medicines. Where do those assessments now…
Organon: What’s Next for the New Merck & Co. Spin-off?
Kevin Ali, the CEO of Organon, the new company formed from the spin-off of Merck & Co.’s women’s health, established brands, and biosimilars businesses, is leading the new, independent company…
Injectable and Solid Dosage Drug Delivery: Key Deals
Drug delivery is important not only for ensuring bioavailability for therapeutic benefit but also for product differentiation and market success. DCAT Value Chain Insights highlights technology advances in drug delivery for injectable…
Ranking the Top 25 Supply Chains: Who Made the Mark?
Supply-chain resiliency and agility are characteristics of companies ranked with the top supply chains according to a recent analysis and ranking by The Gartner Group of the Top 25 supply…
Biosimilars Market Outlook: Uptake Gains Momentum in US
By 2025, $112 billion of biologic medicines will lose exclusivity in the global market. Uptake of biosimilars will gain momentum, especially in the US, which has historically lagged compared to…
Industry, FDA Advance Drug Supply-Chain Security Plan
The bio/pharma industry is moving to meet a November 2023 deadline, under the Drug Supply Chain Security Act (DSCSA), which requires manufacturers to set up electronic systems to track their…
